Tomorrow evening, NASA’s Space Launch System rocket will hurl four astronauts toward the Moon on Artemis II—the first crewed lunar voyage since Apollo 17 in 1972. The world’s cameras will track Commander Reid Wiseman, Victor Glover, Christina Koch, and Canada’s Jeremy Hansen as they loop around the far side of the Moon over ten days. What the cameras will almost certainly miss is the quiet Israeli fingerprint already embedded in every Artemis capsule that follows. That omission tells us something important—not about Israel, but about how we misunderstand the economics of space exploration itself.

Here is the provocation: the new space economy does not reward nations that build entire rockets. It rewards nations that own irreplaceable subsystems—components so specialised, so difficult to replicate, that the mission cannot fly without them. In the language of transaction cost economics, these are relationship-specific assets: investments whose value is highest inside a particular partnership and cannot easily be redeployed elsewhere. Israel, with just over ten million people and a defence burden that consumed 8.8 percent of GDP in 2024—the steepest annual rise since the Six Day War—has no business building a Moon rocket. But it has every business becoming the supplier the Moon rocket cannot do without.

The clearest example is the AstroRad radiation vest, developed by StemRad—an Israeli-American startup born not from a space programme, but from the Fukushima nuclear disaster. When the reactors melted down in 2011, co-founders Oren Milstein and Daniel Levitt recognised that whole-body radiation shielding was impossibly heavy, and that survival hinged on protecting the organs that matter most: bone marrow, lungs, breast tissue, the colon. Their original product, the 360 Gamma vest, was designed for nuclear first responders. The leap to space required compressed polyethylene rather than lead, but the governing insight was identical: selective shielding of stem-cell-rich tissue can save a life while keeping the wearer mobile.

In 2018, NASA, the Israel Space Agency, and the German Aerospace Center agreed to fly the AstroRad on Artemis I, the uncrewed test flight that circled the Moon in 2022. Two female-form mannequins—Zohar, wearing the vest, and Helga, without it—were packed with over 5,600 radiation sensors. The protected mannequin absorbed roughly 60 percent less radiation overall, and 90 percent less in the most sensitive anatomical zones. A senior NASA official overseeing the Artemis programme reportedly responded: “We couldn’t expect better results.”

Sceptics will note that no live astronaut has yet worn the vest on a deep-space mission. They will note that StemRad is a startup, not Lockheed Martin. Fair enough. But consider the alternative. Without wearable protection, a crew caught by a solar particle event beyond the Van Allen belts has one option: huddle behind stowage bags in the capsule’s belly and wait. That is not a safety protocol; it is an admission that the mission architecture has a single point of failure. A vest that cuts exposure by 60 percent converts a crisis into a manageable operational constraint—the difference between aborting a mission objective and completing it. The transaction cost of not having this technology is measured in lost science, lost time, and, eventually, lost lives.

Nor is StemRad an isolated case. The technology migration pattern—solve a problem in one domain, then redeploy the solution laterally—is the structural signature of the Israeli innovation ecosystem. The 360 Gamma vest protects National Guard nuclear response teams on Earth. The AstroRad protects astronauts in cislunar space. StemRad MD shields interventional radiologists from cumulative X-ray exposure during daily procedures. Three markets, one core insight, zero wasted intellectual property. That is not luck. It is a commercialisation model built on minimising the sunk costs of deep research by maximising the number of markets each breakthrough can serve.

Israel’s earlier lunar chapter reinforces the pattern. In 2019, SpaceIL’s Beresheet lander became the first privately funded spacecraft to orbit the Moon, making Israel the seventh country to achieve lunar orbit. Yes, it crashed. And yes, its successor, Beresheet 2, was suspended in 2025 for lack of funding—an uncomfortable fact for the startup nation narrative. But the intellectual property did not crash with the lander. Israel Aerospace Industries licensed the Beresheet design to the American firm Firefly Aerospace for NASA’s Commercial Lunar Payload Services programme. Israeli propulsion and guidance engineering became a structural input to the next generation of American lunar landers. The mission failed; the knowledge migrated. In any serious innovation ecosystem, that is not a contradiction—it is the business model.

This is the argument that Israel’s critics, and frankly some of its boosters, tend to miss. The value of a small nation’s space programme is not measured by whether it can match NASA or the China National Space Administration launch for launch. It is measured by whether it can create capabilities so embedded in the supply chain of larger programmes that its absence would degrade the mission. Radiation protection. Miniaturised guidance systems. Autonomous landing algorithms. Sensor technology tested under the harshest electromagnetic environments on Earth. These are the relationship-specific assets that make Israel not a passenger in the Artemis programme, but a load-bearing component.

Israel signed the Artemis Accords in January 2022, joining nations that have pledged to explore the Moon under shared norms of transparency and peaceful intent. That diplomatic act formalised what the technology had already demonstrated: a country of just over ten million people, whose civilian space agency operates on a fraction of what a single American university spends on its athletics programme, had made itself indispensable to the most ambitious exploration programme in half a century.

As Artemis II lifts off, it is worth remembering that the vest which may one day save an astronaut’s life during a solar storm on the way to Mars was conceived in the shadow of a Japanese nuclear meltdown, engineered in Tel Aviv, co-developed with Lockheed Martin, and tested aboard an American spacecraft carrying a German mannequin named Zohar—Hebrew for “brilliance.”

The name was well chosen. So was the strategy.

© The Times of Israel (Blogs)